Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DHR
HOLDDanaher Corporation · Healthcare · United States · $134.6B · Avg Vol: $1.1B/d
COMPANY DESCRIPTION
Danaher Corporation is a global diversified science and technology innovator operating in Biotechnology, Life Sciences, and Diagnostics, providing analytical instruments, reagents, and services. It benefits from a diversified portfolio of market-leading brands and proprietary technologies in mission-critical scientific and healthcare fields. Its Danaher Business System (DBS) drives operational excellence, innovation, and strategic acquisitions, making it a highly acquisitive conglomerate focused on high-growth segments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.6B | 23.9B | 23.9B | 24.6B | -2.7% | 24.8B | 26.3B | 28.4B | 7.4% |
| EPS | 9.80 | 6.44 | 5.33 | 5.07 | -19.7% | 5.09 | 5.53 | 6.02 | 9.0% |
| Shares | 728.3M | 739.2M | 719.1M | 706.9M | -2.9% | 707.8M | — | — | — |
| Debt | 20.6B | 19.5B | 17.1B | 19.7B | -1.5% | 19.7B | — | — | — |
| Equity | 50.1B | 53.5B | 49.5B | 52.5B | 1.6% | — | — | — | — |
| Op CF | 8.5B | 7.2B | 6.7B | 6.4B | -9.0% | 6.4B | — | — | — |
| Inv CF | -2.2B | -7.1B | -2.0B | -1.2B | — | — | — | — | — |
| Fin CF | -2.6B | -273.0M | -8.4B | -3.0B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DHR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DHR | Danaher Corporation(you) | $134.6B | 58 | HOLD |
| TN8.DE | Thermo Fisher Scientific Inc. | $187.1B | 61 | HOLD |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 60 | HOLD |
| WAT | Waters Corporation | $36.8B | 65 | HOLD |
| NTRA | Natera, Inc. | $37.5B | 51 | HOLD |
| LONN.SW | Lonza Group AG | $46.1B | 44 | HOLD |
| IQV | IQVIA Holdings Inc. | $34.7B | 69 | BUY |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| ICLR | ICON Public Limited Company | $12.8B | 59 | HOLD |
| GH | Guardant Health, Inc. | $19.5B | 47 | HOLD |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.0%